2019年冠状病毒病(COVID-19)
药品
计算生物学
核糖核酸
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
药物反应
病毒学
药理学
不利影响
医学
临床试验
疾病
药物发现
鉴定(生物学)
生物
生物信息学
传染病(医学专业)
基因
遗传学
内科学
植物
作者
Zhihan Wang,Kai Guo,Pan Gao,Qinqin Pu,Min Wu,Changlong Li,Junguk Hur
出处
期刊:Cornell University - arXiv
日期:2020-05-16
被引量:2
摘要
Coronavirus disease 2019 (COVID-19) has impacted almost every part of human life worldwide, posing a massive threat to human health. There is no specific drug for COVID-19, highlighting the urgent need for the development of effective therapeutics. To identify potentially repurposable drugs, we employed a systematic approach to mine candidates from U.S. FDA-approved drugs and preclinical small-molecule compounds by integrating the gene expression perturbation data for chemicals from the Library of Integrated Network-Based Cellular Signatures project with a publicly available single-cell RNA sequencing dataset from mild and severe COVID-19 patients. We identified 281 FDA-approved drugs that have the potential to be effective against SARS-CoV-2 infection, 16 of which are currently undergoing clinical trials to evaluate their efficacy against COVID-19. We experimentally tested the inhibitory effects of tyrphostin-AG-1478 and brefeldin-a on the replication of the single-stranded ribonucleic acid (ssRNA) virus influenza A virus. In conclusion, we have identified a list of repurposable anti-SARS-CoV-2 drugs using a systems biology approach.
科研通智能强力驱动
Strongly Powered by AbleSci AI